Figures & data
Figure 1 Mean pharmacokinetic profiles (serum insulin) over 24 hours after subcutaneous injections of 0.2 U/kg biphasic insulin aspart 30/70 (BIAsp 30 – solid squares) or biphasic human insulin 30/70 (BHI 30 – solid circles) in healthy volunteers. Reproduced with permission from Jacobsen LV, Sogaard B and Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000;56:399–403.Citation27 Copyright © Springer Science and Business Media.
Figure 2 Daily 8-point mean blood glucose profiles after 28 weeks of treatment with BIAsp 30 bid or insulin glargine od (both in combination with metformin, with or without thiazolidinediones). Data from the INITIATE study. *p < 0.05; errors are 2 SE. Reproduced with permission from Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260–265.Citation35 Copyright © 2005 American Diabetes Association.
Figure 3 Significantly greater reduction in HbA1c after 12 weeks’ treatment with BIAsp 30 plus metformin than with BHI 30 plus metformin in obese patients with type 2 diabetes. Errors are SDs. Reproduced with permission from Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with type 2 diabetes. J Endocrinol Invest. 2009; 32(1):23–27.Citation39 Copyright © 2009 Editrice Kurtis.
